A significant paradigm shift in neuropsychiatric treatments could emerge as psychedelics are paired with psychotherapy, rather than used in isolation. The importance of context in clinical trials is emphasized, suggesting that tailored approaches for specific conditions will enhance therapeutic outcomes. The future lies in identifying the right settings and neural circuits to optimize the transformative potential of these substances.
